Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage generative AI–driven drug discovery company, today announced promising first-in-human Phase 1 data for ISM6331, its investigational oral pan-TEAD inhibitor designed using Chemistry42 generative AI platform. Among response-evaluable participants with mesothelioma, the results showed a 40.0% objective response rate (ORR) at 130 mg once daily and an 18.2% ORR with a 68.2% disease control rate (DCR) across the dose cohorts. Findings were presented as a Rapid Oral at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid by Melina E. Marmarelis, MD of Abramson Cancer Center, University of Pennsylvania).

Prof. Theodore Tulchinsky, professor emeritus at the Hebrew University of Jerusalem, has been named the recipient of the APHA 2026 Victor Sidel and Barry Levy Award for Peace, recognizing his contributions to public health cooperation, disease prevention, and the training of healthcare professionals worldwide.

Bone cells called osteocytes help maintain skeletal strength, but how newly formed osteocytes survive remains unclear. Researchers at Washington University School of Medicine found that removing FGFR1 signaling in adult mice disrupted the bone matrix and cellular projections needed for osteocyte communication, leading to cell death in newly formed bone. The findings identify a link between bone matrix organization, osteocyte maturation and survival, offering a foundation for future studies of age-related bone fragility.

The present study suggests that Cryptogenic organizing pneumonia (COP) has a good prognosis. However, relapse is common in COP, occurring in more than 20% of patients. Nearly 50% of relapse occurred within 12 months after diagnosis. Over 60% of relapses contributed to steroid discontinuation; approximately 30% occurred when prednisone was tapered to doses below 10 mg/d. Close follow-up is important for early detection of relapse, especially when steroids are tapered or discontinued.

A retrospective study of 30 patients undergoing awake craniotomy found that 30% experienced new or worsened neurological dysfunction within 48–72 hours after surgery. Early functional and cognitive score reductions were common, while new-onset aphasia occurred in 10% of patients. No statistically significant predictors of acute deterioration were identified. The findings highlight the importance of interpreting early postoperative changes cautiously, as their long-term significance remains uncertain, and conducting larger, prospective, controlled studies with longer-term follow-up.